National Institute of Allergy & Infectious Diseases: HIV Vaccine Candidate Does Not Sufficiently Protect Women Against HIV Infection
September 01, 2021
September 01, 2021
WASHINGTON, Sept. 1 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, . . .
An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, . . .